Anna French, D.Phil., joined Qiming US in 2017 from the Boston Consulting Group (BCG), where she was a healthcare management consultant who advised leading pharmaceutical and biotech companies on their strategy and operations, with a focus in cell therapy and regenerative medicine. Previously, she led a global industry-academic consortium centered on cell therapy commercialization, the Centre for the Advancement of Sustainable Medical Innovation (CASMI)’s Translational Stem Cell Consortium, a partnership between Oxford University and University College London.
Anna is a Partner with the fund and currently serves on the boards of Jasper Therapeutics (NASDAQ: JSPR), Umoja Biopharma, and Auron Therapeutics.
Anna earned a D.Phil. from the University of Oxford, UK, where her research focused on the hematological differentiation of human-induced pluripotent stem (iPS) cells. She has authored over 20 publications in the field of stem cell research. Anna received her BSc in Biochemistry with first class honors from the University of Bristol.